

20 June 2025

EMD presents landmark Medibank deal to largest US Psychedelic Conference

Key Highlights:

- Chief Scientific Officer Dr Michael Winlo invited to deliver two presentations at Psychedelic Science 2025 (PS25), the world's largest psychedelic medicine conference.¹
- Presentations to spotlight Emyria's landmark reimbursement agreement with Medibank.²
- Recognition positions Emyria as a global leader in developing real-world, fundable care models for complex mental health.
- An investor webinar detailing the model is being planned for announcement next week.

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, advises that Chief Scientific Officer and Executive Director Dr Michael Winlo, is currently presenting at Psychedelic Science 2025 ("PS25") in Denver, Colorado, the world's largest psychedelic medicine conference, with over 7,000 attendees¹ and speakers from across healthcare, research, and investment.

Dr Winlo will speak in two prominent sessions:

- **"The Cutting Edge of Care Delivery"**
- **"Reflections from Australia's First Psychedelic Therapy Clinics"**

Central to both talks will be Emyria's recent landmark agreement with Medibank, Australia's largest private health insurer. The multi-year agreement provides reimbursement for eligible members with PTSD to access Emyria's intensive, psychiatrist-led program at Perth Clinic.

Globally, funding remains one of the largest barriers to scaling resource-intensive psychotherapy models. Emyria's model demonstrates how real-world data, ethical care delivery and collaboration with insurers can create sustainable funding pathways.



Figure 1: Main Presentation Stage at PS25

This release has been approved by the Board of Emyria.

For further information, or more on Emyria's approach to mental health care, contact:

Greg Hutchinson
Executive Chair
+61 (0) 8 6559 2800
ghutchinson@emyria.com



Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:

generates

Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.


informs

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

References:

1. <https://maps.org/2024/02/13/psychedelic-science-2025-save-the-date/>
2. See ASX release 18 June 2025
3. <https://www.psychedelicscience.org/>